Case Summary:   

In just ten days, a dedicated researcher in the field of internal medicine secured an EB1A (Alien of Extraordinary Ability) approval through premium processing—a recognition not only of her exceptional scientific acumen but also of the powerful societal relevance of her work. She has become a leading voice in chronic disease epidemiology, COVID-19 variant tracking, and cancer burden analysis.

Navigating the Complex Landscape of Modern Disease

The focus of her research is broad yet deeply interconnected: she studies chronic non-communicable diseases, global health threats such as COVID-19, and rare but deadly cancers like anaplastic thyroid carcinoma. Her contributions bring statistical clarity and public health foresight to some of today’s most urgent medical issues, such as diabetes, cardiovascular disease (CVD), and inflammatory conditions.

Her work has helped public health officials understand how modifiable factors like obesity and poor diet intersect with socio-demographic variables to shape disease outcomes across continents. These insights are not abstract: they influence real-world health policy and intervention design, particularly in high-incidence regions like the United States.

A Scholar with International Reach

With 16 peer-reviewed journal publications, including appearances in The Lancet, Hepatology, eClinicalMedicine, and the Journal of the American College of Cardiology, her scholarship has attracted global acclaim. Her work has been cited over 3,100 times, placing her among the top 1% of internal medicine researchers worldwide over the past four years. Beyond her writing, she has also conducted 15 peer reviews for journals such as Frontiers in Pharmacology and PLoS ONE, reinforcing her credibility as a trusted authority.

Her articles have proven foundational across the medical sciences. For instance, a 2025 paper in Archives of Medical Science used her work on cardiovascular risk factors to highlight the urgent need for dietary interventions and targeted public health policies. Similarly, an international research team studying thyroid carcinoma treatment referenced her epidemiological analyses to justify new therapeutic strategies.

Endorsements from the Pinnacle of Medicine

A professor from a University praised her in a recommendation letter:

“[Client’s] research has highlighted trends in modifiable risk factors like obesity, poor diet, and air pollution, providing much-needed epidemiological evidence for guiding public health policies, preventive strategies, and personalized treatment approaches.”

These sentiments were echoed by experts at the Mayo Clinic, the Harvard T.H. Chan School of Public Health, and the Icahn School of Medicine at Mount Sinai—many of whom had never met her but recognized her work’s scholarly and societal significance.

From Data to Public Benefit

Our team at NAILG showcased her extraordinary ability by emphasizing both the depth of her publication and citation record and the breadth of her real-world influence. Her EB1A petition stood out not only for meeting multiple regulatory criteria but for demonstrating, under the Kazarian framework, that she truly belongs to that small group at the top of her field.

This story is not just about an immigration victory—it’s about recognizing science that saves lives, policies that protect communities, and research that bridges continents. We are honored to have played a part in this researcher’s journey to the United States, where her extraordinary ability will continue to serve the national and global good.